CEL-SCI prices offering

Expecting gross proceeds of $10M, CEL-SCI Corp. (CVM -10.6%) prices its best efforts public offering at $1.40/unit. Each unit consists of one share of common stock plus 0.25 warrant to purchase one share of common. The warrants expire on October 17, 2014 and are immediately exercisable at $1.58.

Closing date is April 17.

Proceeds to fund its Phase 3 clinical trial, R&D and general corporate purposes.

Comments (4)
  • janicegross
    , contributor
    Comments (2) | Send Message
    When I purchase the stocks using my warrants is the money used to purchase the warrant just added cost to the stock price? i.e. warrant .43 cents plus $1.25 cost of stock to equal total cost of $1.68 ? I am a novice at this and I do not really know what I am doing.
    Thanks to anyone who can give me some information.
    14 Apr 2014, 01:00 PM Reply Like
  • matherapist
    , contributor
    Comments (24) | Send Message
    I understand the need to raise money to support things, but every time they do this (and this is about the 3rd or 4th time since I have owned the stock), the value to me is diluted for a time. I bought on the recent pull back from 1.80, and the next day they drop the stock value to $1.15 in the unit. I hope they succeed in their test.
    14 Apr 2014, 01:01 PM Reply Like
  • wiser235
    , contributor
    Comment (1) | Send Message
    Cel is one of the most promising companies in the cancer treatment non toxic materials.
    Phase 3 is going well so far ,and more and more are enrolling to use the multikine.
    The potential is huge!!
    15 Apr 2014, 03:35 AM Reply Like
  • cancerman321
    , contributor
    Comment (1) | Send Message
    This is the third time the did a reverse split. Back in 1990 I brought 1000 shares at $1.49 and in 1994 I brought additional 500 shares at $1.91. Well some years later the did reverse split and I ended up with 150 shares. Now with this round of reverse split I ended up with 15 shares. The next reverse split I will have 1 share or a fraction of it. Stay away from this company. The only revenue they get is from grants and stock sell which they turn around and make it worthless then when you originally paid for it. They have been working of this cancer treatment for 24 years. They first started with trying to make a vaccination for HIV. Then came along the Multkine for brain and neck cancer. People be careful out there.
    15 Jun 2014, 07:53 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs